| scholarly article | Q13442814 |
| P2093 | author name string | Guolian Xia | |
| Ronglin Jiang | |||
| P2860 | cites work | Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients | Q48880047 |
| Evaluation of the performance of a modified Acute Physiology and Chronic Health Evaluation (APACHE II) scoring system for critically ill patients in emergency departments in Hong Kong | Q56785102 | ||
| Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis | Q84812716 | ||
| Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update | Q85920475 | ||
| Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update | Q88050972 | ||
| Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America | Q88172637 | ||
| Pharmacokinetics and drug metabolism of antibiotics in the elderly | Q91715802 | ||
| Resistance reported from China antimicrobial surveillance network (CHINET) in 2018 | Q93065997 | ||
| The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) | Q26768286 | ||
| Urinary tract infections: epidemiology, mechanisms of infection and treatment options | Q27022487 | ||
| Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America | Q28273425 | ||
| The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey | Q28547409 | ||
| Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients | Q28550492 | ||
| APACHE II: a severity of disease classification system | Q29547729 | ||
| High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria | Q33754471 | ||
| Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system | Q34300253 | ||
| How to treat VAP due to MDR pathogens in ICU patients | Q35457068 | ||
| Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline | Q35689185 | ||
| Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review | Q35948788 | ||
| Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia | Q36757628 | ||
| Clinical pharmacokinetics and pharmacodynamics of tigecycline | Q37590845 | ||
| Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin | Q37778205 | ||
| Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. | Q38433744 | ||
| Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study | Q38477582 | ||
| Structural characterization of an alternative mode of tigecycline binding to the bacterial ribosome | Q39564833 | ||
| Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints | Q40744728 | ||
| Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. | Q40937010 | ||
| Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation | Q41014948 | ||
| Monocyte deactivation--rationale for a new therapeutic strategy in sepsis | Q41219022 | ||
| Active screening of multi-drug resistant bacteria effectively prevent and control the potential infections | Q41652677 | ||
| Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia | Q42905606 | ||
| Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis | Q43127750 | ||
| Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation | Q46108407 | ||
| P433 | issue | 10 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | e19466 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis | |
| P478 | volume | 99 |
Search more.